



Stock Code : 4180

TWi Pharmaceuticals, Inc.

Notice of 2017 Annual Shareholders' Meeting (Summary translation)

- I. The 2017 Annual Shareholders' Meeting (the "Meeting") will be convened at 2F., No.12, Zhouzi St., Neihu Dist., Taipei City (The shareholders meeting admission time will start at 08:30 a.m. at the meeting venue) at 9:00 a.m. on June 12, 2017 (Monday). The agenda for the Meeting is as follows:
 1. Reports on Company Affairs :
 - (1) 2016 Business Report.
 - (2) 2016 Audit Committee's Review Report.
 - (3) Report on Accumulated Losses Reaching One-Half of Paid-in Capital and Execution Status of the Improvement Plan of the Operation of the Company for the fourth quarter 2016.
 - (4) Report on the Implementation for Treasury Share Buyback Program.
 - (5) Amendment to the Operation with Integrity & Good Faith Guidelines.
 - (6) Amendment to the Ethical Behavior Guidelines.
 2. Proposals :
 - (1) Adoption of the 2016 Business Report, Financial Statements and Consolidated Financial Statements.
 - (2) Adoption of the Proposal for 2016 Deficit Compensation.
 - (3) Amendments to the Plan of Use of Fund of Capital Increase through New Share Issuance in order to Facilitate the Issuance of Overseas Depositary Receipts.
 3. Discussions :
 - (1) Amendment to the Company's Articles of Incorporation.
 - (2) Amendment to the Procedures for Election of Directors.
 - (3) Amendment to the Operational Procedures for Acquisition and Disposal of

Assets.

(4) Proposal of Release the Prohibition on Directors from Participation in Competitive Business.

4. Questions and Motions

II. Non-competition restrictions on the directors to be released:

1. Pursuant to Article 209 of the Company Act, a director who “acts for himself or on behalf of another person, and whose act falls within the scope of the company’s business, shall explain at the meeting of the shareholders the essential details of such act and obtain approval at the shareholders’ meeting.
2. In order to be aided from the professional expertise and relevant experience of the Company's directors, and under the premise of no violation to the interests of the Company, it was requested that the Shareholders' Meeting agree on releasing the non-competition restrictions of the Company's Directors. The act of participation in competitive business of the Directors is as in the following table:

Name of director	Act of participation in competitive business	Name of institutional shareholder represented	Business invested by such institutional shareholder
Chen, Chih-Ming	1. Chairman of Xin Chen Investment Co., Ltd. 2. Director of Hefei NORATECH Pharmaceutical Co. Ltd. 3. Director of Great Success Holdings Ltd. 4. Director of Twin City Management Ltd. 5. Director of Shining Armour Holding Inc. 6. Director of Summer Breeze Development Ltd. 7. Director of AG Global Inc. 8. Director of Calchen Holdings Co. Ltd. 9. Director of Ahura Assets Limited. 10. Chairman of Hefei Xin Chen Business Management Consultant Co., Ltd.	-	-
Liu, Nien-Hua	G.M. of NRT Pharmaceuticals, Inc.	Opulent Assets Holdings Ltd.	1. AG Global Inc. 2. NRT Pharmaceuticals, Inc.
Sun, Ching-Feng	Independent director of ASLAN Pharmaceuticals.	-	-
Lin, Dong-Han	Corporate Director's Representative of Formosa Laboratories, Inc.,	-	-
Su, Yu-Hui	Corporate Director's Representative of	-	-

	Eminent Venture Capital Corp.,		
--	--------------------------------	--	--

- III. Please find the Notice of Attendance and Proxy Form enclosed with this Meeting Notice. If you plan to attend the meeting in person, please affix your signature or personal seal to the Sign-in Card and submit it for registration on the day of the shareholders' meeting. If you wish to appoint a proxy to attend the meeting, please fill out the name and relevant information of the proxy, affix your signature or personal seal to the Proxy Form, have the proxy affix his or her signature or personal seal to the Proxy Form. Such proxy form shall be delivered to the Company's securities agent at the Register and Transfer Agency division of CTBC Bank Corporation, at least five (5) days prior to the meeting so that a sign-in card can be issued to the proxy.
- IV. If any shareholder solicits proxies, the Company will publish a summary of such solicitation on the Securities and Futures Commission website (<http://free.sfi.org.tw>). For shareholders who wish to make inquiries, please access the "free inquiry system for published information on proxies" page on the website, click on "entrance to published information on proxies", and enter the search criteria.
- V. This annual general meeting allows shareholders to exercise their proxy votes by correspondence or by electronic means. Please login to the Taiwan Depository & Clearing Corporation stock vote platform website (<http://www.stockvote.com.tw>) to exercise your proxy vote between May 13rd, 2017 to June 9th, 2017. Proxy forms and electronic voting auditing and verification services will be provided by the stock transfer division of CTBC Bank Corporation.
- VI. The institution responsible for tallying and verifying the votes for the Company is the Register and Transfer Agency division of CTBC Bank Corporation.

Sincerely Yours

The Board of Directors of TWi Pharmaceuticals, Inc.